Related Experiment Video
Updated: Sep 7, 2025
09:53
In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge
Published on: June 15, 2018
7.6K
Specific microRNAs and heart failure: time for the next step toward application?
Radka Sigutova1,2, Lukas Evin3, David Stejskal1
1Institute of Laboratory Medicine, Department of Clinical Biochemistry, University Hospital Ostrava and Department of Biomedical Sciences, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.
Summary
Selected microRNAs show promise as biomarkers for heart failure, aiding diagnosis and treatment. Further research and standardized lab methods are needed for clinical application.
Area of Science:
- Biochemistry
- Molecular Biology
- Cardiology
Background:
- MicroRNAs (miRNAs) play critical roles in cardiovascular disease pathophysiology.
- Specific miRNAs are implicated in myocardial hypertrophy, fibrosis, and heart failure.
Purpose of the Study:
- To review current knowledge on selected miRNAs in heart failure.
- To explore their potential in diagnosis, prognosis, and therapy.
- To discuss laboratory determination methods.
Main Methods:
- Literature review focusing on specific miRNAs (miR-21, miR-1, miR-23a, miR-142-5p, miR-126, miR-29, miR-195, miR-499).
- Analysis of their association with myocardial hypertrophy and fibrosis.
- Evaluation of clinical applications and laboratory techniques.
Main Results:
- Several miRNAs are key indicators of cardiac pathological changes.
- Clinical utility as biomarkers and therapeutic targets is promising but requires more data.
- Standardization of laboratory procedures is essential for routine use.
Conclusions:
- Selected miRNAs hold significant potential for diagnosing and managing heart failure.
- Further research is necessary to overcome current limitations in clinical application.
- Optimized and affordable laboratory analysis methods are crucial for integrating miRNAs into cardiovascular care.
